Latigo Biotherapeutics, Inc.
LTGODrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Experimental: LTG-001 High Dose | Phase 2 | Acute Pain | - | - |
LTG-001 High Dose | Phase 2 | Acute Pain, Postoperative | - | - |
Frequently asked questions
What is in Latigo Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Latigo Biotherapeutics, Inc.'s (LTGO) pipeline across Phase 2. Its lead program is Experimental: LTG-001 High Dose (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Latigo Biotherapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Latigo Biotherapeutics, Inc. (LTGO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LTGO biotech catalysts?→
Add LTGO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Latigo Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.